Schizophrenia Clinical Trial
— DAiPOfficial title:
Experimentation of a Protocol of Psychiatric Advance Directives: Randomized Controlled Multi-site Trial
Verified date | March 2022 |
Source | Assistance Publique Hopitaux De Marseille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Severe mental illness is accompanied by cognitive fluctuations that can alter decision-making skills and lead to coerced care. Taking into account, on the one hand, the health, social and economic impact of forced hospitalization, on the other hand the importance of self-determination, the reinforcement of the power to act in the evolution of these disorders, new strategies to better reflect the views of people have been developed. Among these, the drafting of Advanced Directives in Psychiatric (ADP), allows people with mental disorders to write while their decision-making skills are restored care instructions in case of decompensation. It is a tool of "advanced therapeutic education" and early prevention of relapses. It is hypothesized that the implementation of drafting accompanied by advance directives to people with severe psychiatric disorders decreases in the short term the number of forced hospitalization care pathway of these people, compared to the subjects having not benefited from this device. This research will take the form of a randomized controlled trial on 3 sites. The "quantitative" evaluation component of results and processes will be completed with a qualitative anthropological and socio-political evaluation component documenting the trajectories of individuals and the implementation of the program, as well as a "participatory research" component aimed at a dialogue between users, researchers and professionals. The patient who is a beneficiary of the "Advanced Directives in Psychiatric" program will be encouraged to complete the " Advanced Directives in Psychiatric" document and will receive support in drafting them. The non-beneficiary patient of the program will follow up with his psychiatrist unchanged. The experimental design of the quantitative component is based on an experimental, randomized, prospective, controlled, parallel study, comparing two groups of subjects with severe psychiatric disorders. This research will assess the effectiveness, efficiency and impact of the " Advanced Directives in Psychiatric" program compared to conventional psychiatric care alone. Ultimately, the objective of describing the effects of the program on health organizations and on the representations and practices of professionals, caregivers and users is at the service of a better understanding of the conditions of possibility of the generalization of this experimentation.
Status | Completed |
Enrollment | 399 |
Est. completion date | January 2, 2022 |
Est. primary completion date | May 10, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - over 18 years old; - diagnosed with schizophrenia, bipolar I disorder, or schizoaffective disorder - receiving ambulatory care by a treating psychiatrist, investigator - having been hospitalized under duress at least once during the year preceding the inclusion - being in decision-making jurisdiction - can be under curator - agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under guardianship. Exclusion Criteria: - less than 18 years old; - participating in another study simultaneously - in situations of decision-making incompetence - not able to read and write - refusing to participate in the study, or the legal representative refusing to participate in the study in the case of a person under guardianship. |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hôpitaux de Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of patients with compulsory admission | Evaluation of the hospitalization rate by comparing the two groups | 12 months | |
Secondary | Evaluation of patient recovery rates | The rate is assessed by the Recovery Assessment Scale (RAS) | 12 months | |
Secondary | Evaluation of the empowerment rate | The rate is assessed by the Empowerment Scale (ES) | 12 months | |
Secondary | Measuring the health-related quality of life of patients | Health-related quality of life is measured using a specific scale: the S-QOL. It is a self-reported instrument of 41 items that assesses the quality of life in patients with schizophrenia | 12 months | |
Secondary | Measuring mental health symptoms of patients | Mental health symptoms are measured by Modified Colorado Symptom Index (MCSI) | 12 months | |
Secondary | Evaluation of the therapeutic alliance between the patient and his psychiatrist | The therapeutic alliance between the patient and his psychiatrist is assessed by the 4-Point Alliance Self Report (4-PAS) questionnaire | 12 months | |
Secondary | Measuring Disease Awareness | Disease Awareness is assessed by the évaluée par l'échelle SUMD (Scale to Assess Unawareness in Mental Disorder | 12 months | |
Secondary | Evaluation of the severity of the psychiatric disorder by the psychiatrist | The severity of the psychiatric disorder is assessed by the Clinical Global Impression (ICG) scale | 12 months | |
Secondary | Medico-economic analysis (cost-utility) | Number of inpatient | 12 months | |
Secondary | Medico-economic analysis (cost-utility) | Number of emergency department visits | 12 months | |
Secondary | Medico-economic analysis (cost-utility) | Number of outpatient visits | 12 months | |
Secondary | Medico-economic analysis (cost-utility) | Loss of productivity | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |